Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
estimated completion

Description

Summary

Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 for the treatment of patients with (1) relapsed/refractoryR/R or locally advanced solid tumors (Phase 1/2) or (2) R/R AML (Phase 1 only).

Official Title

Phase 1/2 Study of RTX-240 Monotherapy

Details

This is a Phase 1/2, open label, multicenter, multidose, first-in-human (FIH) dose escalation and expansion to determine the safety and tolerability, recommended phase 2 dose and optimal dosing interval, pharmacology, and antitumor activity of RTX-240 in adult patients with relapsed/refractory or locally advanced solid tumors (Phase 1/2) or relapsed/refractory acute myeloid leukemia (Phase 1 only). RTX-240 is a cellular therapy that co-expresses 4-1BBL and IL-15TP, a fusion of IL-15 and IL-15 receptor alpha, with the goal of harnessing the innate and adaptive immune systems for the treatment of cancer. The study will include a monotherapy dose escalation phase followed by an expansion phase in specified tumor types.

Keywords

Solid Tumor, AML Adult RTX-240

Eligibility

You can join if…

Open to people ages 18 years and up

  • Signed written informed consent obtained prior to study procedures
  • Patients ≥18 years with an ECOG 0 or 1 (Parts 1 and 2) or 0-2 (Part 3).
  • Relapsed/Refractory (R/R) or locally advanced, unresectable solid tumor for which no standard therapy exists (Parts 1 and 2), or for which the patient is ineligible or has declined standard therapyR/R, cytologically confirmed AML (Part 3).
  • Disease must be measurable per Response Evaluation Criteria
  • The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior therapy, before initiation of study treatment.
  • Adequate Organ Function as Defined by the protocol:
  • GFR ≥ 50 mL/min/1.73,
  • AST and ALT ≤ 3 × the ULN and total bilirubin ≤ 1.5 × ULN,
  • In the absence of cancer within the liver, or AST and ALT ≤ 5 × ULN and total bilirubin ≤ 3 × ULN, in the setting of primary or metastatic liver tumors.
  • ANC ≥ 10 × 103/μL and platelet count ≥ 100 × 103/μL without myeloid growth factor support or transfusion, respectively, for at least one week.
  • Hemoglobin should be ≥ 9 g/dL without red blood cell transfusion for at least two weeks.
  • Patients must have LVEF ≥ 45%
  • Patients enrolling into Part 2 of the study must be diagnosed with a solid tumor that has been selected for an expansion cohort

You CAN'T join if...

  • Primary central nervous system (CNS) malignancy or CNS involvement, unless asymptomatic, previously treated, and stable without steroids (Parts 1 and 2) or known CNS leukemia (Part 3).
  • Known hypersensitivity to any component of study treatment or excipients.
  • Positive antibody screen using institution's standard type and screen test.
  • Clinically significant, active and uncontrolled infection, including human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
  • Clinically significant coagulopathy, uncontrolled hypertension or autoimmune hemolytic anemia
  • Leukemic blast count ≥25 x 103/µL (Part 3)
  • Concomitant conditions requiring active immunosuppression
  • Grade 3 immune related Adverse Event (irAE)
  • Prior malignancy within the past 3 years, with protocol specified exceptions

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92093 United States
  • The Angeles Clinic & Research Institute accepting new patients
    Los Angeles California 90025 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Rubius Therapeutics
ID
NCT04372706
Phase
Phase 1/2
Study Type
Interventional
Last Updated